Biopharma and venture capital: a deep dive

Deep pools of private capital have become available to young drug developers in the past few years. The pandemic triggered a new flood of cash, but the inflows of money had already picked up some time before, with Covid-19 merely reinforcing a new appreciation of the sector’s attributes.